Navigation Links
EntreMed Reports Clinical Program Progress and Company Update
Date:11/12/2008

ments within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate

Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Angeles, CA (PRWEB) , ... August 31, 2015 , ... When it comes to undergoing ... to the top of the head. Adding more volume to the hair on top ... procedure for patients who have a good amount of donor hair on other areas of ...
(Date:8/31/2015)... ... , ... The Lisle family law firm of Momkus McCluskey, LLC ... peers to earn a “Leading Lawyers” distinction. , The “Leading Lawyers” ... Illinois. The nomination process is based on statewide peer survey nominations and the approval ...
(Date:8/31/2015)... Dayton, Ohio (PRWEB) , ... August 31, 2015 ... ... Jenny Michael as Vice President, Marketing and Corporate Communications. In this capacity, Michael ... , CareSource is an industry leader in consumer-focused programs that have contributed ...
(Date:8/31/2015)... Carolina (PRWEB) , ... August 31, 2015 , ... The ... Laurels on Tuesday, September 1. , “Alive Inside” shadows a social worker who ... & MEMORY?.” , “It’s a documentary about bringing music to residents in health care ...
(Date:8/31/2015)... ... 31, 2015 , ... David L. Chalnick, M.D., the medical ... first doctors in the area to perform minimally invasive hip replacement surgery. Over ... recovery, decreased immediate and long-term pain, and an accelerated return to normal activity. ...
Breaking Medicine News(10 mins):Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4
... has found that major surgeries and operations could prove deadly ... showed that elderly men with even slightly irregular red blood ... major surgery. ,The study, which examined data from ... to demonstrate that even minor anaemia or polycythemia, when the ...
... the wrappers of the diabetes drug Avandia will soon start ... congestive heart failure . ,Some of the experts, ... that the delay in implementation is an example of industry ... ,GlaxoSmithKline's Avandia has been in use since 1999. The ...
... number of panthers is slowly on the rise . ... estimates of the census figures indicated an increase in the ... to the 2004 wildlife census, there were over 550 panthers ... Park, has the maximum number at 83. At least 15 ...
... Bean will soon be available in the South Asian markets, ... licensing agent for India, Pakistan, Bangladesh and Nepal has inked ... popular character portrayed by Rowan Atkinson to the South Asia ... the television producer of the popular comedy series Mr. Bean. ...
... keep children as safe as possible in cars, leaving parents ... major review of restraint legislation, accident statistics and parent surveys ... graduate to an adult seatbelt without the use of ... or about 11 years old, and that children under 12 ...
... Taking serious note of doctors using advertisements to lure ... Monday asked the state's medical council to take steps ... education and research minister Tikshan Sood said here that ... but also a violation of the Medical Council Act. ...
Cached Medicine News:Health News:Major Surgeries and Operations Could Prove Deadly for Anaemic Older Men 2Health News:Child Car Seat Danger 2
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: